US Dollar vs Yen

登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Vertex Pharmaceuticals Inc (VRTX)
Vertex Pharmaceuticals Inc (VRTX) ニュース

VRTX

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:VRTX

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/08/13	05 : 08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/08/09	05 : 06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/08/09	00 : 47	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/08/08	08 : 12	Business Wire	Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/08/07	22 : 52	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/08/03	05 : 10	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/08/03	05 : 03	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/08/02	05 : 17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/08/02	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/08/02	05 : 01	Business Wire	Vertex Reports Second Quarter 2024 Financial Results	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/08/02	04 : 34	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/07/31	04 : 25	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/07/31	02 : 10	Business Wire	Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/07/26	05 : 06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/07/25	05 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/07/25	01 : 27	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/07/23	02 : 16	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/07/18	05 : 13	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/07/15	22 : 00	PR Newswire (Canada)	Santé Canada autorise la commercialisation de TRIKAFTA(MD) (éléxacaftor/tézacaftor/ivacaftor et ivacaftor) chez les personnes atteintes de fibrose kystique âgées de 2 ans et plus présentant certaines mutations rares	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/07/15	22 : 00	PR Newswire (Canada)	Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/07/13	05 : 07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/07/10	23 : 27	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/07/02	21 : 33	Business Wire	Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/07/02	05 : 05	Business Wire	Vertex to Announce Second Quarter 2024 Financial Results on August 1	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/06/22	04 : 45	Business Wire	Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/06/20	20 : 15	Business Wire	Vertex Announces Extended Long-Term Reimbursement Agreement with NHS England for Access to Cystic Fibrosis Medicines KAFTRIO®, SYMKEVI® and ORKAMBI®	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/06/14	16 : 03	Business Wire	Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/06/14	05 : 11	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/06/14	05 : 09	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc
2024/06/12	22 : 56	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VRTX	Vertex Pharmaceuticals Inc

Showing the most relevant articles for your search:NASDAQ:VRTX

1 2 3 4 5 6 7 8 9 10 次へ >>

US Dollar vs Euro

Invesco QQQ Trust Series 1

BNP Paribas (QX)

American Express

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約